Croatia Pharmaceutical Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Market Size (2024) | USD 1.73 Billion |
| Market Size (2029) | USD 2.25 Billion |
| CAGR (2024 - 2029) | 5.36 % |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Croatia Pharmaceutical Market Analysis
The Croatia Pharmaceutical Market size is estimated at USD 1.73 billion in 2024, and is expected to reach USD 2.25 billion by 2029, growing at a CAGR of 5.36% during the forecast period (2024-2029).
The factors driving the growth of the Croatian pharmaceutical market include active government support to enhance domestic pharmaceutical R&D capabilities, the presence of various key players in the country, and the rising number of investments by top biopharmaceutical companies.
The active support from the Croatian government for enhancing domestic pharmaceutical R&D capabilities is projected to drive market growth significantly during the forecast period. For instance, the Research Infrastructure Development Roadmap of the Republic of Croatia 2023-2027, published by the Ministry of Science and Education, provides a strategic framework for enhancing the country's scientific and technological capabilities. This document outlines the government's commitment to developing state-of-the-art research facilities and fostering a supportive environment for scientific innovation. By investing in research infrastructure, Croatia aims to accelerate pharmaceutical R&D, attract international collaborations, and enhance its competitiveness in the global market. These advancements are essential for driving long-term growth and sustainability in the pharmaceutical industry.
The presence of various key players in the country, ensuring adequate manufacturing and supply of pharmaceutical drugs, is projected to drive market growth during the forecast period. For instance, companies like Phoenix Farmacija and Propharma play significant roles in the Croatian pharmaceutical industry. Phoenix Farmacija, a major pharmaceutical wholesaler and distributor, offers a wide range of healthcare products and services, ensuring robust supply chain management and distribution efficiency across Croatia. Propharma's comprehensive pharmaceutical services, including logistics and market access support, contribute to the industry's growth by enhancing the availability and accessibility of pharmaceutical products. Together, these companies ensure that essential medications reach consumers efficiently, underlying the industry's expansion and reliability.
Furthermore, the rising number of investments by top biopharmaceutical companies in Croatia to establish their manufacturing facilities is also projected to drive market growth during the forecast period. For instance, in June 2022, Pfizer and Sobi inaugurated the construction of a new production plant in Croatia with an investment of around EUR 100 million (USD 110.3 million). The plant is expected to be completed by the end of 2024. The substantial investment in a new plant near Zagreb indicates confidence in the local market's potential and will significantly boost local production capabilities. This facility may focus on biopharmaceuticals, adding high-value products to Croatia's pharmaceutical portfolio. It will position Croatia as a competitive player in the biopharmaceutical industry, attracting further investments and fostering innovation.
Thus, these factors collectively illustrate a vibrant and growing pharmaceutical market in Croatia, driven by strategic investments, enhanced distribution networks, improved research infrastructure, and robust economic performance. However, the country's stringent regulatory scenarios may hinder market growth during the forecast period.
Croatia Pharmaceutical Market Trends
The Anti-diabetic Segment is Expected to Register Significant Growth During the Forecast Period
Croatia is facing a growing diabetes burden, which is estimated to drive the demand for pharmaceutical drugs for the treatment and management of this health condition in the country. For instance, according to the data accessed from the IDF in May 2024, there were around 212.7 thousand people suffering from diabetes in 2021, and the number is estimated to increase to 213.2 thousand by 2030.
Similarly, according to an article published by the University of Zagreb, Croatia, in December 2022, around 20,000 individuals in the country suffered from type 1 diabetes, and second-generation insulin analogs are available for treatment with multiple daily injections. Thus, the prevalence of diabetes mellitus in Croatia, coupled with the availability of second-generation insulin analogs for treatment, is driving the growth of the anti-diabetes segment in the Croatian pharmaceutical market.
Therefore, the rising prevalence of diabetes is projected to drive the demand for anti-diabetes drugs during the study period.
The Branded Drugs Segment is Expected to Register Fastest Growth During the Forecast Period
The growth of the branded drugs segment in the Croatian pharmaceutical market can be attributed to several factors, such as the high economic growth, rising geriatric population, and surging chronic diseases.
The prevalence of chronic diseases, such as diabetes, cardiovascular diseases, and cancer, is on the rise in Croatia, which is projected to spur the demand for branded drugs in the country during the forecast period. For instance, according to the data published by the Global Cancer Observatory in May 2024, there were around 28,809 new cancer cases in Croatia in 2022. As per the same source, colorectal cancer cases recorded the highest number at 4,190, followed by lung cancer at 3,649 and prostate cancer at 3,247. Thus, the number of cancer cases in the country is projected to drive the demand for branded drugs to treat these conditions due to their established efficacy and brand recognition.
In addition, doctors may prefer prescribing branded drugs due to their familiarity with these medications, perceived efficacy, and patient trust in the brands. Pharmaceutical companies often engage in extensive marketing and education efforts for healthcare professionals. For instance, according to an article published by Fitch Solutions Inc. in September 2022, Croatia is projected to become a more attractive destination for international drugmaker investment. As per the same source, Pfizer launched a new production plant in Croatia in 2022, increasing its presence and positively impacting future pharmaceutical exports. Also, Croatia joined the eurozone in January 2023, facilitating pharmaceutical trade and investments.
Therefore, significant investments, like Pfizer’s new production plant, indicate increased capacity for pharmaceutical exports. Croatia joining the eurozone in 2023 is expected to further boost trade and investment, making the country more appealing to international pharmaceutical companies. These developments are likely to drive the growth of the branded drugs segment in Croatia.
Therefore, factors such as the rising number of chronic diseases and significant investments in the country are projected to drive the demand for branded drugs during the forecast period.
Croatia Pharmaceutical Industry Overview
The Croatian pharmaceutical market is competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some prominent players are actively engaging in acquisitions and joint ventures to consolidate their market positions in the country. The key companies dominating the market include Johnson & Johnson, Novartis International AG, Merck & Co. Inc., Pfizer Inc., and Bayer AG
Croatia Pharmaceutical Market Leaders
-
Johnson & Johnson
-
Novartis International AG
-
Pfizer Inc.
-
Bayer AG
-
Merck & Co., Inc.
*Disclaimer: Major Players sorted in no particular order
Croatia Pharmaceutical Market News
- May 2024: Alkaloid AD Skopje initiated a project worth EUR 19.4 million (USD 20.82 million) to construct solid pharmaceutical form manufacturing facilities covering an area of 6,200 square meters. This marked the company's most significant investment in the past two decades.
- October 2023: The European Organisation for Research and Treatment of Cancer (EORTC) and the Menarini Group (Menarini) launched a new study for breast cancer patients. It is called EORTC 2129-BCG TREAT ctDNA, a clinical trial supported by the EORTC Breast Cancer Group.
Croatia Pharmaceutical Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.1.1 Healthcare Expenditure (Govt. Vs Private)
4.1.2 Pharmaceutical Imports and Exports
4.1.3 Epidemiology Data For key Diseases
4.1.4 Regulatory Landscape/Regulatory Bodies
4.1.5 Licensing and Market Authorization (For both Local Production and Imported Goods)
4.1.6 Pipeline Analysis
4.1.6.1 By Phase
4.1.6.2 By Sponsor
4.1.6.3 By Disease
4.1.7 Statically Overview
4.1.7.1 Number of Hospitals
4.1.7.2 Employment in the Pharmaceutical Industry
4.1.7.3 R&D Expenditure
4.1.8 Ease of Doing Business
4.2 Market Drivers
4.2.1 Rising Healthcare Expenditure
4.2.2 Rising Incidence of Chronic Disease
4.3 Market Restraints
4.3.1 Stringent Regulatory Scenario
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Therapeutic Category
5.1.1 Anti-infectives
5.1.2 Cardiovascular
5.1.3 Gastrointestinal
5.1.4 Anti-diabetic
5.1.5 Respiratory
5.1.6 Dermatological
5.1.7 Musculoskeletal System
5.1.8 Nervous System
5.1.9 Other Therapeutic Categories
5.2 By Drug Type
5.2.1 Prescription Drug
5.2.1.1 Branded Drugs
5.2.1.2 Generic Drugs
5.2.2 OTC Drugs
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Merck & Co. Inc.
6.1.3 Novartis International AG
6.1.4 Pfizer Inc.
6.1.5 Sanofi SA
6.1.6 F. Hoffmann-La Roche AG
6.1.7 AstraZeneca PLC
6.1.8 Eli Lilly and Company
6.1.9 Novartis International AG
6.1.10 GlaxoSmithKline PLC
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Croatia Pharmaceutical Industry Segmentation
As per the scope of this report, pharmaceuticals are referred to as prescribed and non-prescription drugs. These medicines can be bought by an individual with or without a doctor's prescription and are consumed to treat various diseases. The report also covers the in-depth analysis of qualitative and quantitative data.
The Croatian pharmaceutical market is segmented by therapeutic category and drug type. By therapeutic category, the market is segmented into anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, respiratory, dermatological, musculoskeletal system, nervous system, and other therapeutic categories. By drug type, the market is segmented into prescription drugs and OTC drugs. By prescription drugs, the market is segmented into branded drugs and generic drugs. For each segment, the market size and forecast are provided in terms of value (USD).
| By Therapeutic Category | |
| Anti-infectives | |
| Cardiovascular | |
| Gastrointestinal | |
| Anti-diabetic | |
| Respiratory | |
| Dermatological | |
| Musculoskeletal System | |
| Nervous System | |
| Other Therapeutic Categories |
| By Drug Type | ||||
| ||||
| OTC Drugs |
Croatia Pharmaceutical Market Research FAQs
How big is the Croatia Pharmaceutical Market?
The Croatia Pharmaceutical Market size is expected to reach USD 1.73 billion in 2024 and grow at a CAGR of 5.36% to reach USD 2.25 billion by 2029.
What is the current Croatia Pharmaceutical Market size?
In 2024, the Croatia Pharmaceutical Market size is expected to reach USD 1.73 billion.
Who are the key players in Croatia Pharmaceutical Market?
Johnson & Johnson, Novartis International AG, Pfizer Inc., Bayer AG and Merck & Co., Inc. are the major companies operating in the Croatia Pharmaceutical Market.
What years does this Croatia Pharmaceutical Market cover, and what was the market size in 2023?
In 2023, the Croatia Pharmaceutical Market size was estimated at USD 1.64 billion. The report covers the Croatia Pharmaceutical Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Croatia Pharmaceutical Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Croatia Pharmaceutical Industry Report
Statistics for the 2024 Croatia Pharmaceutical market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Croatia Pharmaceutical analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
